NCT00421213View on ClinicalTrials.gov

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Hematologic NeoplasmsBone Marrow NeoplasmsNon-Hodgkin's Lymphoma
Interventions
DRUG

Darinaparsin

300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.

Trial Locations (6)

Unknown

Miami

Chicago

Bethesda

Fargo

Sioux Falls

Morgantown

Sponsors
All Listed Sponsors
lead

Alaunos Therapeutics

INDUSTRY